“Alison’s leadership in commercial planning and strategy has been a
tremendous asset as we transition to a fully-integrated commercial-stage
company,” said
Alison has been promoted to chief commercial officer after joining
bluebird as senior vice president, marketing and product launch in
August of 2015. Prior to joining bluebird, she spent 21 years at
“It’s truly inspirational to see our science moving from the clinic to becoming potential therapies for patients and their families living with severe genetic diseases and cancer,” said Ms. Finger. “I look forward to continuing to work with our outstanding team on this next phase of exciting development and growth for bluebird.”
Alison is currently a member of the board of directors of the
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio's gene therapy clinical programs include its Lenti-D™ product
candidate for the treatment of cerebral adrenoleukodystrophy, and its
LentiGlobin® product candidate for the treatment of
transfusion-dependent β-thalassemia, also known as β-thalassemia major,
and severe sickle cell disease. bluebird bio's oncology pipeline is
built upon the company's leadership in lentiviral gene delivery and T
cell engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T cell
receptor (TCR) therapies. bluebird bio's lead oncology programs, bb2121
and bb21217, are anti-BCMA CAR T programs partnered with
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the timing of potential regulatory approval and commercial launch of the
Company’s product candidates. Any forward-looking statements are based
on management’s current expectations of future events and are subject to
a number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in our clinical studies,
risks that the current or planned clinical trials of the LentiGlobin
drug product will be insufficient to support regulatory submissions or
marketing approval in the
View source version on businesswire.com: http://www.businesswire.com/news/home/20180214005218/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Media:
Stephanie Fagan, 201-572-9581
sfagan@bluebirdbio.com
or
Investors:
Elizabeth
Pingpank, 617-914-8736
epingpank@bluebirdbio.com